Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.66 |
| ▸ | CASP2 | P42575 | 1/20 | 0.60 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634653 | 1.00 | FAAH (0.66) | FAAHCASP2NAAAEPHX1NAMPT | |
| SCHEMBL23713358 | 1.00 | FAAH (0.66) | FAAHCASP2NAAAEPHX1NAMPT | |
| SCHEMBL23471072 | 0.98 | FAAH (0.62) | FAAHCASP2NAAAEPHX1NAMPT | |
| SCHEMBL27986572 | 0.92 | FAAH (0.70) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL13296412 | 0.92 | FAAH (0.55) | FAAHCASP2NAAAEPHX1NAMPT | |
| SCHEMBL21105956 | 0.92 | FAAH (0.57) | FAAHCASP2NAAAEPHX1NAMPT | |
| SCHEMBL22802143 | 0.92 | FAAH (0.57) | FAAHCASP2NAAAEPHX1NAMPT | |
| SCHEMBL13857031 | 0.90 | FAAH (0.67) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL11846148 | 0.89 | FAAH (0.66) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL21096710 | 0.88 | FAAH (0.65) | FAAHCASP2NAAAEPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | FAAH 3663/4885CASP2 1181/4885NAAA 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.